PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1995 May; 58(5): 625–628.
PMCID: PMC1073498

Peripheral neuropathy associated with simvastatin.

Abstract

Four patients are described who developed sensorimotor neuropathy while being treated with simvastatin and had complete or partial resolution of clinical abnormalities after withdrawal of treatment. In one case onset was within days of commencing treatment, but in two cases symptoms did not develop for two years. The electrophysiological and pathological features of the neuropathy were those of axonal degeneration. Clinical evidence of proximal and distal weakness and muscle fasciculations and persistent abnormalities of sensory conduction after recovery suggest the possibility of toxic damage to anterior horn cells and dorsal root ganglia. Thirty eight other cases with symptoms suggestive of peripheral neuropathy have been reported to the Australian Adverse Drug Reactions Advisory Committee, 22 of whom recovered after cessation of treatment; in five cases there was recurrence after re-exposure to the drug. Simvastatin should be considered among the causes of peripheral neuropathy, and the drug should be withdrawn if patients receiving it develop muscle weakness or sensory disturbances.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (709K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981 Aug 27;305(9):478–482. [PubMed]
  • Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol. 1991 Nov 1;68(11):1127–1131. [PubMed]
  • Walker JF. Simvastatin: the clinical profile. Am J Med. 1989 Oct 16;87(4A):44S–46S. [PubMed]
  • Stalenhoef AF, Mol MJ, Stuyt PM. Efficacy and tolerability of simvastatin (MK-733). Am J Med. 1989 Oct 16;87(4A):39S–43S. [PubMed]
  • England JD, Viles A, Walsh JC, Stewart PM. Muscle side effects associated with simvastatin therapy. Med J Aust. 1990 Nov 5;153(9):562–563. [PubMed]
  • Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin. Clin Chem. 1992 Aug;38(8 Pt 1):1504–1504. [PubMed]
  • Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet. 1989 Nov 4;2(8671):1097–1098. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group